Skip to main content
. 2020 May 27;52(5):843–853. doi: 10.1038/s12276-020-0443-8

Fig. 4. Serial monitoring of serum VEGF, IL-6, CRP, and ESR levels at baseline and at 6 months after treatment with conventional DMARD (c-DMARD) versus biologic DMARD (b-DMARD).

Fig. 4

a–d Changes in serum levels of VEGF, IL-6, CRP, and ESR in c-DMARD users (n = 53). The left panel shows good or moderate responders (n = 40), and the right panel shows nonresponders (n = 13). e–h Changes in serum levels of VEGF, IL-6, CRP, and ESR in b-DMARD users (n = 49). The left panel shows good or moderate responders (n = 41), and the right panel shows nonresponders (n = 8). EULAR response criteria were used to define good responders, moderate responders, and nonresponders in the two groups. Ns = not significant, **p < 0.01, ***p < 0.001 by the paired t test.